Menu
Sativa Wellness Group Inc have been recently featured on the news.financial website in an interesting article written by Stefan Feulner.
A link to this article can be found below.
Sativa Wellness Group inc. (LON:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk Interviews to discuss its first quarterly profit in Q2 2021. Geremy talks us through the results highlights and explains the companies plans for the second half.
Sativa Wellness Group Inc’s (LON:SWEL) (CSE: SWEI) Geremy Thomas talks to Proactive London’s Katie Pilbeam about their Q1 2021 financial statements.
Sativa Wellness Group Inc’s (LON:SWEL) Geremy Thomas talks to Proactive London’s Katie Pilbeam about subsidiary PhytoVista Laboratories , which has been was granted ISO/IEC 17025:2017 accreditation from the UK for the testing of cannabinoids.
Sativa Wellness Group Inc. (LON:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk to discuss now being listed on the UK government website to offer 2 and 8 day quarantine tests. Geremy explains where they are with the clinic roll-out and how this will impact revenues.
SATIVA Wellness’ pivot to Covid-19 testing work has exceeded expectations with plans afoot to open up a dozen new locations delivering blood tests, vaccines and vaccine boosters.
Previously know as The Sativa Group the name change to Sativa Wellness in October last year reflected its efforts in the fight against the pandemic.
read more…
Sativa Wellness Group Inc. (AQSE:SWEL / CNSX:SWEL) Executive Chairman Germey Thomas joins DirectorsTalk Interviews to discuss reaching its £1m milestone for COVID testing. Geremy talks us through the milestone, the addition of further testing clinics including two mobile units, the significance of having 30 clinics to the company and how long Geremy thinks the PCR testing revenue stream will last.
Sativa Wellness Group Inc’s (LON:SWEL) Geremy Thomas talks to Proactive London’s Katie Pilbeam about its coronavirus (COVID-19) testing business which has now achieved over £1.1mln worth of bookings in less than four months since opening its first clinic in Bath, UK.
The company now has 17 operational clinics throughout the UK testing for COVID-19, in line with its target to have 30 clinics by the end of April.
Sativa Wellness Group Inc. (AQSE:SWEL / CNSX:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk to discuss its operations meeting the requirements of Good Manufacturing Practice and Good Hygiene Practice standards for food manufacturing. Geremy explains what this means for the company, the impact this has on the Novel Foods accreditation and now with David Beckham as a competitor, how he feels about that.
Sativa Wellness Group Inc’s (LON:SWEL) Geremy Thomas talks to Proactive London about being back at the helm with his focus on generating cash and profit as well as reducing costs.
He says, ‘since I’ve been in place we’ve seen a doubling of our share price and I think that will continue to rise‘.
Sativa Wellness Group Inc. (CNSX:SWEL) Executive Chairman Geremy Thomas joins DirectorsTalk Interviews to discuss its novel food application to the FSA. Geremy explains why he has re-joined the board, the significance of the application announcement and the recent success of new listings in this CBD sector.
Sativa Group PLC‘s (LON:SATI) Geremy Thomas caught up with Proactive London’s Andrew Scott following the opening of their first cannabidiol (CBD) wellness retail outlet in Bath at the weekend.
The Goodbody Wellness store was launched on Friday evening by Crispin Blunt, MP for Reigate and co-chair of the All Party Parliamentary Group for Drug Policy Reform.
Geremy Thomas, founder and chief executive of Sativa Investments PLC (LON:SATI), caught up with Proactive London’s Andrew Scott to discuss the NEX-based medical cannabis investor’s trading and strategic update.
Sativa’s this week unveiled plans to become a first-mover seed-to-consumer business in the UK.
Geremy Thomas, chief executive of Sativa Investments PLC (NEX:SATI), tells Proactive’s Andrew Scott they’ve agreed to buy PhytoVista Laboratories, a UK-based lab that tests cannabis oils and hemp products, for £435,000.
Sativa Investments PLC’s Geremy Thomas tells Proactive that the medicinal cannabis market has seen explosive growth all over the world, particularly in Vancouver, Canada.
He adds that Sativa has a unique position in the UK market that allows UK investors to benefit from companies in regulated markets.
